1. Introduction {#s0005}
===============

Recently, China faces an increasing burden of type 2 diabetes and its vascular complications with approximately 11.6% of overall prevalence in adults ([@bb0130]). People with diabetes impose about 3.38 times higher cost than those with normal glucose intolerance, while the cost will be 3.75 times higher for patients with longer duration of diabetes (≥ 10 years) compared with those with shorter duration (≤ 5 years) due to its complications ([@bb0135]). Therefore, it\'s important to conduct precise strategies to treat patients with diabetes effectively. Actually, clinical trials demonstrated that more intensive blood pressure lowering and glucose control yielded evident clinical benefits for diabetes patients with vascular endpoints ([@bb0155]).

On the other hand, inter-individual variation of drug response was observed in prophylactic medications for diabetes and its comorbidities ([@bb0115]), which may be partially explained by accumulating the pharmacogenetics evidence. However, the influence of common genetic variations on the individual difference in drug response or clinical endpoints need to be confirmed by large and long-term follow-up studies, because of the progressive feature of type 2 diabetes mellitus (T2DM), and the mechanisms in molecular levels that related to clinical heterogeneity phenotype remains unclear.

Human tribbles homolog 3 (TRIB3, also called NIPK, SINK, TRB3, SKIP3) is a pseudokinase that can inhibit Akt by physically occupying its phosphorylation sites, which plays a pivotal role on subsequent insulin signaling ([@bb0040]). Previous reports indicated that TRIB3 has a ubiquitous cellular functions by interacting with a host of molecules establishing a mechanic link between metabolic phenotypes and cardiovascular risk traits ([@bb0125], [@bb0110]), renal diseases ([@bb0035]), tumor progression ([@bb0060]) in T2DM. Interestingly, in vitro study data showed *TRIB3* genetic variation (c.251 A \> G, Gln84Arg, rs2295490) does not affect its protein level, but impacts on insulin-stimulated Akt (Thr308, Ser473) and eNOS (Ser1177) phosphorylation, which results in 2 to 3 times of decreased eNOS activity and nitric oxide production ([@bb0015]). On another hand, valsartan (an antihypertensive drug), could significantly down-regulate the expression of *TRIB3* mRNA levels and improve the cardiac functions in rats with diabetic cardiomyopathy ([@bb0140]). Moreover, The presence of the gain-of-function mutation in *TIRB3*(rs2295490) is one of a leading cause of TRIB3 over-activity and subsequent Akt inhibition, which has linked to increased risk of cardiovascular diseases by metabolic syndrome, endothelial and/or cardiac dysfunction ([@bb0100]). Therefore, we considered that TRIB3 may have an impartible role in mediating the development of the diabetic vascular complications by regulating insulin signal transduction pathway and (or) by regulating blood pressure homeostasis in patients with type 2 diabetes. And the relationship between *TRIB3* genetic variation and diabetes and its vascular complications merits further attention.

The achievement of therapeutic goals for plasma glucose, lipid and blood pressure levels is important to decrease the vascular diseases risk in patients with diabetes ([@bb0070]). Although some evidence showed that a common *TRIB3* genetic variation (rs2295490) was a risk factor for diabetic nephropathy, atherosclerosis, and coronary artery disease ([@bb0090], [@bb0030], [@bb0045], [@bb0055]), some low-frequency genetic variants, which are detected by re-sequencing of *TRIB3*, can partially account for cardiovascular clinical outcomes in diabetes ([@bb0105]). However, systematical study on the relationship between *TRIB3*genetic variant (rs2295490) and antidiabetic or antihypertensive drug response, vascular complications, especially in a large and long-term follow-up T2DM clinical trial cohort have not been reported. The aim of this study is to explore the effects of *TRIB3* genetic variation (rs2295490) on the clinical outcomes of vascular events after blood pressure lowering and glucose controlling treatment.

2. Methods {#s0010}
==========

2.1. Patients {#s0015}
-------------

We conducted a retrospective study on the cohort from Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) clinical trial at 61 centers in China, with a follow-up period of 5 years. Approval to conduct the trial was obtained from the ethics committee of each study center, and all participants provided written informed consent (registration number [NCT00145925](ctgov:NCT00145925){#ir0005}). Detailed rationale, design, follow-up schedule and clinical endpoints of ADVANCE trial have been described in previous studies ([@bb0005], [@bb0010]). In brief, it was a 2 × 2 factorial randomized controlled trial. Patients with type 2 diabetes were randomly assigned (1:1) to receive perindopril-indapamide or matching placebo for blood pressure lowering, and modified-release gliclazide based intensive or local standard therapy for glycaemic control. For blood lowering cohort, participants were treated for 6 weeks as run-in period with combination of perindopril and indapamide, then randomly grouped into fixed combination regimen (perindopril/indapamide, initially 2.0/0.625 mg daily, increasing to 4.0/1.25 mg daily after 3 months) or matching placebo. For glucose controlling group, an open label, randomized protocol was implemented to an intensive glucose control or to local standard therapy based on local guidelines. The intensive glucose control was defined as the use of gliclazide modified release based regimen (30--120 mg daily) and other oral agents, then insulin aiming for a hemoglobin A1c (HbA1c) value of 6.5% or lower. The local standard treatment was defined as the patients who continue with their usual glucose control regimens, which may include any therapy except the use of gliclazide.

The major vascular endpoints include death from cardio-cerebral vascular diseases, nonfatal stroke or nonfatal myocardial infraction, and new or worsening renal or diabetic eye disease. Other vascular events such as cerebrovascular events (include death due to cerebrovascular disease, stroke, transient ischemic attack, and subarachnoid hemorrhage), coronary events (include myocardial infarction, angina pectoris, myocardial ischemia, and sudden death), heart disease (coronary heart disease, heart failure, atrial fibrillation), new or worsening microalbuminuria, and visual deterioration were also evaluated both jointly and separately. In our study, there was no other pre-specified criterion for the levels of blood pressure, HbA1c or other baseline clinical characteristics at entry. A total of 1884 patients from 61 clinical centers were successfully genotyped in *TRIB3* (rs2295490) by Sanger sequencing.

2.2. Genotyping Procedure for *TRIB3* {#s0020}
-------------------------------------

Genotyping of *TRIB3* rs2295490 was determined by PCR-direct sequencing. The PCR primers for *TRIB3* (rs2295490) were as follows: the sense primer, 5′GTTGCCCCTGA-GCCCACCTACT3′; and the antisense primer, 5′TCCCTGGATGCTTCCCCACTAA3′, with a production length of 286 bp. The reaction mixture (25 μl) contained: 10 × PCR buffer (2.5 μl), 10 × dNTP (2.5 μl), 10 μM of each of the sense and antisense primers (0.5 μl), H~2~O (16.8 μl), g - DNA (2 μl), Taq-ase (0.2 μl). Temperature cycling was proceeded as follows: initial denaturation for 5 min at 94 °C, followed by 36 cycles of 30 s at 94 °C, annealing at 57 °C for 30 s, and elongation at 72 °C for 30 s, and a terminal extension for 5 min. Genotypes were determined without knowledge of the status of patients and 10% blinded. Random DNA samples from the patients were genotyped twice with 100% concordance. Sequencing was assisted by Shanghai Majorbio Bio-pharmTechnology Company.

2.3. Statistical Analysis {#s0025}
-------------------------

All the analyses were performed with SPSS (version 20.0 for windows; Chicago, IL). Allele frequencies were determined by the genotypes of all the participants. Continuous data are presented as mean values ± SD, and frequencies or percentages are for categorical variables. The Hardy--Weinberg equilibrium analysis was carried out for the study participants using the χ^2^-test. Differences in baseline characteristics among the phenotypes were assessed by independent-samples *t*-test or Wilcoxon rank sum test, appropriately. General linear model-multivariate ANOVA and linear regression analysis was performed in plasma glucose, lipid levels and blood pressure between *TRIB3* (rs2295490) AA, AG + GG genotype with adjustment for sex, age, duration of the disease, body mass index (BMI), combined medication and drug dosage. Cox backword (LR: entry *p* = 0.05 and removal *p* = 0.10) regression model adjustment by history of vascular disease, baseline of the clinical biochemical data, sex, age, duration of the disease, combined medication and drug dosage was used to investigate the relationship between genetic variation and the risk of clinical outcomes of vascular event endpoints. A two-tailed *P*-value \< 0.05 was considered significant.

3. Results {#s0030}
==========

3.1. Genotyping and Characteristics of Patients {#s0035}
-----------------------------------------------

A total of 1898 Chinese participants were enrolled from May 2002 to December 2002 in ADVANCE trial (China centers) from 61 hospitals, with an median of 4.8 years follow-up duration in 1714/1884 (91.0%) participants who were successfully completed at scheduled end of follow-up ([Fig. 1](#f0005){ref-type="fig"}), and 1884/1898 (99.3%) of DNA samples from these patients passed quality control for genotyping of *TRIB3* (rs2295490). Genotyping data of *TRIB3* (rs2295490) in our study cohort showed a minor allele (G) frequency of 17.1%, the (AA, AG and GG) genotype frequencies were 1230/1884 (65.3%), 581/1884(30.8%) and 73 (3.9%), respectively, which were in Hardy-Weinberg equilibrium across the randomized groups (Table S1 in the Supplementary Appendix). No significant difference was observed across the baseline characteristics at entry between AA and AG + GG genotype of *TRIB3* (rs2295490) in blood pressure lowering or glucose controlling axis ([Table 1](#t0005){ref-type="table"}).

3.2. Glucose Controlling Axis {#s0040}
-----------------------------

For the intensive glucose controlling group, the mean glycosylated HbA~1c~ level was 6.8% throughout the follow-up period, and it was higher in patients with AG + GG genotypes (6.7%) compared to AA genotype (6.6%) after a follow-up of 6 months, while the difference observed was not significant until the period between 15 and 30 months (AA vs AG + GG, 6.6% vs 6.8%) ([Fig. 2](#f0010){ref-type="fig"}a). For the standard glucose control group, the mean glycosylated HbA~1c~ levels was 7·4% throughout the follow-up period, and it showed no significant difference between AA and AG + GG genotypes (AA vs AG + GG, 7.4% vs 7.4%) after randomized treatment ([Fig. 2](#f0010){ref-type="fig"}b). Additionally, in the intensive and standard glucose treatment groups, fast plasmid glucose and HbA1c levels between AA and AG + GG genotypes showed a similar trend, although not significant (data not shown).

A total of 458 patients had major macrovascular or microvascular events during the visits: 152/621 (24.5%) patients with AA genotype and 61/319 (19.1%) with AG + GG genotype (hazard ratio, 1.46; 95% CI, 1.06 to 2.17; *p* = 0.018) were observed in the intensive glucose control group ([Fig. 3](#f0015){ref-type="fig"}a); 143/609 (23.5%) patients with AA genotype and 102/335 (30.4%) with AG + GG genotype (hazard ratio, 0.72; 95% CI, 0.55 to 0.94; *p* = 0.016) were observed in the standard glucose control group ([Fig. 3](#f0015){ref-type="fig"}b). Additionally, *TRIB3* (rs2295490) genetic variation showed an inverse effect on the major macrovascular events ([Fig. 3](#f0015){ref-type="fig"}c and d) and microvascular events ([Fig. 3](#f0015){ref-type="fig"}e and f) when compared between the two groups, and the effects on the secondary clinical outcomes of coronary ([Fig. 3](#f0015){ref-type="fig"}g and h) and cerebrovascular events ([Fig. 3](#f0015){ref-type="fig"}i and j) are similar as well. There was no significant difference in other major and secondary macrovascular or microvascular events when analyzed jointly or separately, except for the secondary clinical endpoints of new or worsening microalbuminuria and death from any cause ([Table 2](#t0010){ref-type="table"}).

3.3. Blood Pressure Controlling Axis {#s0045}
------------------------------------

Over the duration of follow-ups, the mean systolic blood pressure (SBP) was 132.8 mm Hg and diastolic blood pressure (DBP) 74.6 mm Hg in perindopril--indapamide fix tablet treatment group; while the mean SBP was 137.8 mm Hg and DBP 76.9 mm Hg in placebo matching treatment group. In the randomized active blood lowering treatment group, compared with *TIRB3* (rs2295490) AA genotype carriers, patients with AG + GG genotype had a mean decrease of DBP of 0.8 mm Hg. Marginally significant difference (*p* = 0.063) between the two groups at the end of follow-up was observed ([Fig. 4](#f0020){ref-type="fig"}a). Conversely, in matched placebo treatment group, the mean DBP was increased by 1.0 mm Hg respectively ([Fig. 4](#f0020){ref-type="fig"}b). However, SBP presented no remarkable difference between the AA and AG + GG groups (data not shown).

For blood pressure lowering axis, there was no significant effect of *TRIB3* (rs2295490) genetic variation on the risk of any major and secondary clinical outcomes between the active and placebo treatment groups (Table S2 in the Supplementary Appendix). However, it is worth noting that the genetic variation was weakly correlated to the risk of total coronary events in the active treatment group (hazard ratio, 1.52; 95% CI, 0.98 to 2.35; *p* = 0.061) ([Fig. 4](#f0020){ref-type="fig"}c), but not in the matched placebo treatment group (hazard ratio, 1.04, 95% CI, 0.67 to 1.02; *p* = 0.85) ([Fig. 4](#f0020){ref-type="fig"}d).

4. Discussion {#s0050}
=============

For the intensive glucose control axis, as data shown in [Fig. 2](#f0010){ref-type="fig"}, *TRIB3* (rs2295490) genetic variation had a significant influence on patients that were assigned to the intensive glucose control group, but not on patients assigned to the standard glucose control group. For the intensive glucose control group, the gliclazide MR-based, along with other mainly prescribed drugs such as metformin, insulin preparations were required to make the glycated hemoglobin value target to 6.5% or lower. For the standard glucose control group, however, a routine administration of metformin and sulphonylureas (except gliclazide) glucose control strategies was recommended. The main difference in the clinical medication between the two groups was that the proportion of insulin combination treatment. Interestingly, TRIB3 is a pseudo-kinase that plays a pivotal role in the insulin signaling transduction pathway ([@bb0040]), and *TRIB3* (rs2295490) G allele can lead to a gain-of-function amino acid substitution in the insulin target tissues ([@bb0075]). In addition, the genetic variation dose not directly affect fast blood glucose levels, but by altering the interplay between insulin sensitivity and secretion ([@bb0095]), our results were in accordance with these findings.

Besides, our data showed that *TRIB3* (rs2295490) genetic variation had a significant clinical relevance to macrovascular or microvascular clinical outcomes. We were surprised to find that *TRIB3* (rs2295490) genetic variation played a reverse role between intensive and standard glucose control groups ([Fig. 5](#f0025){ref-type="fig"}). Subgroup analysis further confirmed that patients with G allele had greater benefits in the macrovascular and microvascular events from patients with intensive glucose treatment, mainly as a consequence of a reduction in the major microvascular and all coronary clinical outcomes ([Fig. 3](#f0015){ref-type="fig"}e and g). For the patients in the standard glucose control group, however, the G allele was a risk factor of major macrovascular and cerebrovascular clinical outcomes ([Fig. 3](#f0015){ref-type="fig"}d and j). Our sub-center data illustrated that the incidence of major microvascular events was significantly reduced in the intensive glucose control when compared with the standard glucose control (hazard ratio, 0.72; 95% CI, 0.56 to 0.94; *p* = 0.016) (Fig. s1 in the Supplementary Appendix), and it was consistent with the results reported previously ([@bb0085]). Data from Zhang et al. have revealed that the induction of TRIB3 by high glucose was reversed to baseline by euglycemia achieved in vivo and in vitro ([@bb0150]). It is suggested that the significant difference in blood glucose levels between intensive and standard glucose control groups may be a leading cause to the reverse role of *TRIB3* (rs2295490) genetic variation between the two groups, while the exact mechanism needs to be confirmed by further research.

For the blood pressure lowering axis, we found that *TRIB3* (rs2295490) genetic variation was not significantly associated with the blood pressure response after a fixed combination therapy of perindopril and indapamide. Interestingly, when taking *TRIB3* (rs2295490) AA genotype as the baseline, patients carrying *TRIB3* (rs2295490) AG + GG genotype had a flip effect on diastolic blood pressure response in a fixed combination of perindopril and indapamide treatment group compared with placebo matching treatment group ([Fig. 4](#f0020){ref-type="fig"}a and b). However, there was no significant difference between AA and AG + GG genotypes in the two groups on the incidence of major macrovascular, microvascular, coronary and cerebrovascular outcomes when analyzed jointly or separately. The more frequent use of perindopril, calcium channel blockers (CCBs) (57% and 33% at the end of follow-up, respectively) in the placebo group than the active treatment group (43% and 26% at the end of follow-up, respectively) might be relevant for such results. Details are shown in [Fig. 4](#f0020){ref-type="fig"}a and b.

However, in the continuous blood pressure lowering group, irrespective of initial blood pressure levels, *TRIB3* (rs2295490) G allele carriers in the active treatment group got more benefit on coronary events when compared with placebo group, although the difference was not significant. Limited data ([@bb0015], [@bb0140], [@bb0065], [@bb0020]) and our findings indicate that TRIB3 mediated signaling pathway may be related to blood pressure regulation and its genetic variation can affect the response of blood pressure lowering drugs, subsequently affect cardiovascular event outcomes. At this point, it is necessary to conduct further study.

Recently, investigation of common genetic variability in type 2 diabetes patients with cardiovascular complications from VNDS study showed that the genetic variations in gatekeepers along the insulin signaling pathway (*IRS1*, *ENPP1* and *TRIB3*) were associated with increased coronary heart disease ([@bb0120]). It is suggested that investigation of genetic variation in other new or key genes, which are related to insulin signaling pathway may have higher clinical value and significance ([@bb0080], [@bb0025]). However, up to now, the allele gene frequencies of the related genetic variations in *TRIB3* (except rs2295490 mutation) are rare in Chinese population (\< 1%). In addition, results from large-scale sequencing did not support any major role of lower-frequency variants in type 2 diabetes neither ([@bb0050]). Therefore, we appropriately selected rs2295490 as candidate single nucleotide polymorphism (SNP) for our study.

5. Conclusion {#s0055}
=============

In this study, our findings include: 1) during follow-up period, a partially difference in glucose and blood pressure response were observed after the intensive and the active treatment between *TRIB3* (rs2295490) AA and AG + GGgenotype, it suggests this gene polymorphism may have a plausible effect on antidiabetic and antihypertensive drug response in patients with T2DM. 2) *TRIB3* (rs2295490) genetic variation was associated with the clinical outcomes of major macrovascular and microvascular complications in T2DM, while the effects of this genetic variation has a reverse role between the intensive and standard glucose control groups, which can be caused by the obvious differences in glucose levels between the two groups. 3) Our findings suggest that good glucose and blood pressure control exhibited greater benefits on vascular outcomes in patients with *TRIB3* (rs2295490) G allele.
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![Effects of *TRIB3* (rs2295490) genetic variation on HbA~1c~ (%) levels at baseline and during follow-ups between intensive and standard glucose control groups. Data are shown as mean ± SEM, *p*-values were estimated from stepwise linear regression model with adjustment for sex, age, duration of the disease, body mass index (BMI), combined medication and drug dosage between *TRIB3* (rs2295490) AA and AG + GG genotypes at the visit time.](gr2){#f0010}

###### 

Effects of *TRIB3* (rs2295490) genetic variation on the cumulative hazard function of clinical endpoints according to glucose control strategy. The major vascular endpoints include death from cardiovascular disease, stroke or myocardial infraction, and new or worsening renal or diabetic eye disease. Other vascular events such as cerebrovascular events (include death due to cerebrovascular disease, stroke, transient ischemic attack, and subarachnoid hemorrhage), coronary events (include myocardial infarction, angina pectoris, myocardial ischemia, and sudden death). Vertical broken lines indicate additional information on microvascular events (diabetes related nephropathy and retinopathy) were obtained at 24-month and 48-month visits. And the event times were recorded as the visit dates. The curves were truncated at Month 57, by which time 99% of events had occurred. The effects of treatment between *TRIB3* (rs2295490) AA and AG + GG genotypes (hazard ratios and *p*-values) were estimated from survival-cox regression models with backward LR adjustment for baseline available data.
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![Effects of *TRIB3* (rs2295490) genetic variation on diastolic blood pressure response and coronary clinical outcomes during follow-up between perindopril/indapamide and placebo treatment groups. Data of Panel a and b are shown as mean ± SEM, *p*-values were estimated from stepwise linear regression model with adjustment for sex, age, duration of the disease, body mass index (BMI), combined medication and drug dosage between *TRIB3* (rs2295490) AA and AG + GG genotypes at the visit time. Coronary events include myocardial infarction, angina pectoris, myocardial ischemia, and sudden death. The effects of treatment on coronary events between *TRIB3* (rs2295490) AA and AG + GG genotypes (hazard ratios and *p*-values) were estimated from survival-cox regression models with backward LR adjustment for baseline available data (panel c and d).](gr4){#f0020}

![Analysis of *TRIB3* (rs2295490) genetic variation and treatment-specific interaction in glycaemic control arm. Vertical broken lines indicate additional information on microvascular events (diabetes related nephropathy and retinopathy) were obtained at 24-month and 48-month visits. And the event times were recorded as the visit dates. The curves were truncated at Month 57, by which time 99% of events had occurred. The effects of *TRIB3* (rs2295490) genotypes and treatment-specific interaction in glycaemic control arm (hazard ratios and *p*-values) were estimated from survival-cox regression models with backward LR adjustment for baseline available data.](gr5){#f0025}

###### 

Baseline characteristics of all participants in the subgroup according to *TRIB3* (251, A \> G) genotype in the blood pressure lowering or glucose controlling groups.

Table 1

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                   Active drug (n = 934)   Placebo (n = 950)   Intensive control (n = 940)   Standard control (n = 944)                                          
  ---------------------------------------------------------- ----------------------- ------------------- ----------------------------- ---------------------------- ------------ ------------ ------------ ------------
  Age (years), mean (SD)                                     65(6)                   65(5)               65(6)                         64(6)                        65(6)        65(6)        65(6)        65(6)

  Male, n (%)                                                299(49)                 165(51)             342(55)                       163(50)                      315(51)      152(48)      326(54)      176(53)

  Duration of diabetes† (years), median (IQR)                7(3‐ 11)                7(3--11)            7(3--11)                      7(3 − 12)                    7(3--12)     7(3--11)     7(3--11)     7(3--12)

  Previous vascular disease                                                                                                                                                                                

  History of major macrovascular disease, n (%)              109(18)                 60(18)              120(19)                       67(20)                       117(19)      60(19)       112(18)      67(20)

  History of myocardial infarction, n (%)                    23(4)                   9(3)                24(4)                         13(4)                        22(4)        9(3)         25(4)        13(4)

  History of stroke, n (%)                                   90(15)                  51(16)              103(17)                       56(17)                       102(16)      52(16)       91(15)       55(16)

  History of major microvascular disease, n (%)              80(13)                  52(16)              91(15)                        39(12)                       78(13)       46(14)       93(15)       45(13)

  History of macroalbuminuria ‡, n (%)                       46(8)                   26(8)               52(8)                         21(6)                        44(7)        22(7)        54(9)        25(8)

  History of microvascular eye disease§, n (%)               37(6)                   30(9)               44(7)                         21(6)                        38(6)        27(9)        43(7)        24(7)

                                                                                                                                                                                                           

  Blood pressure assessment                                                                                                                                                                                

  Systolic blood pressure (mm Hg), mean (SD)                 140(21)                 139(22)             141(22)                       138(19)                      140(21)      137(21)      141(21)      140(21)

  Diastolic blood pressure (mm Hg), mean (SD)                79(11)                  78(11)              79(11)                        78(10)                       79(11)       78(11)       79(11)       77(11)

  History of currently treated hypertension, n (%)           390(64)                 216(66)             396(64)                       211(64)                      389(63)      212(67)      397(65)      215(64)

                                                                                                                                                                                                           

  Blood glucose assessment                                                                                                                                                                                 

  Glycated hemoglobin (%), mean (SD)                         7.7(1.8)                7.8(1.8)            7.7(1.7)                      7.6(1.8)                     7.7(1.8)     7.8(1.9)     7.7(1.8)     7.7(1.8)

  Fasting plasma glucose (mmol/l), mean (SD)                 8.7(3.0)                9.0(3.3)            8.5(2.8)                      8.7(2.9)                     8.7(3.0)     8.9(3.2)     8.5(2.8)     8.8(3.1)

                                                                                                                                                                                                           

  Other major risk factors                                                                                                                                                                                 

  Current smokers, n (%)                                     139(23)                 73(22)              158(25)                       71(22)                       150(24)      69(22)       147(24)      75(22)

  Total cholesterol (mmol/L), mean (SD)                      5.4(1.2)                5.4(1.2)            5.3(1.2)                      5.3(1.3)                     5.4(1.2)     5.4(1.3)     5.4(1.2)     5.2(1.2)

  High-density lipoprotein (mmol/L), mean (SD)               1.3(0.5)                1.3(0.5)            1.3(0.5)                      1.3(0.5)                     1.3(0.5)     1.3(0.5)     1.3(0.5)     1.3(0.5)

  Low-density lipoprotein (mmol/L), mean (SD)                3.3(1.0)                3.2(1.0)            3.2(1.0)                      3.2(1.1)                     3.2(1.1)     3.3(1.1)     3.2(1.0)     3.1(1.0)

  Triglyceride (mmol/l), mean (SD)                           2.0(1.6)                2.1(1.5)            2.0(1.5)                      2.0(1.4)                     1.9(1.4)     2.2(1.7)     2.1(1.7)     1.9(1.2)

  Urinary albumin:creatinine ratio (mg/mmol), median (IQR)   2.4\                    2.3\                2.5\                          2.4\                         2.4\         2.6\         2.4\         2.1\
                                                             (1.1--7.5)              (1.2--8.1)          (1.1--6.7)                    (1.1--6.2)                   (1.2--7.0)   (1.1--8.0)   (1.1--7.0)   (1.1--6.9)

  Body-mass index (kg/m2), mean (SD)                         25(3)                   25(3)               25(3)                         25(3)                        25(3)        25(3)        25(3)        25(3)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

† Durations of diabetes are shown as the age at first visit minus age when diabetes first diagnosed. ‡ Urinary albumin-creatinine ratio \> 33.9 mg/mmol was defined as macroalbuminuria. § Proliferative diabetic retinopathy, retinal photocoagulation therapy, macular oedema, or blindness related to diabetes are defined as microvascular eye diseases.

###### 

Effects of *TRIB3* (c.251, A \> G) genetic variation on patients with major and secondary outcomes according to glucose-control strategy.

Table 2

  Subgroup                                          Intensive, n (%)   HR (95% CI), *P*-value   Standard n (%)            HR (95% CI), *P*-value               
  ------------------------------------------------- ------------------ ------------------------ ------------------------- ------------------------ ----------- -------------------------
  Major clinical outcomes                                                                                                                                      
  Combined major macro- and micro-vascular events   152(24.5)          61(19.1)                 1.46(1.06--2.17), 0.018   143(23.5)                102(30.4)   0.72(0.55--0.94), 0.016
  Major macrovascular events                        89(14.3)           39(12.2)                 1.28(0.86--1.90), 0.22    73(12.0)                 57(17.0)    0.66(0.46--0.96), 0.028
  MI                                                14(2.3)            7(2.2)                   0.91(0.34--2.46), 0.86    13(2.1)                  13(3.9)     0.47(0.21--1.04), 0.061
  Stroke                                            60(9.7)            28(8.8)                  1.14(0.72--0.82), 0.57    55(9.0)                  40(11.9)    0.70(0.45--1.06), 0.093
  Death from Cardio-cerebral vascular cause         27(4.3)            8(2.5)                   2.27(0.91--5.65), 0.078   21(3.4)                  13(3.9)     0.78(0.33--1.84), 0.57
  Major microvascular events                        75(12.1)           28(8.8)                  1.62(1.02--2.58), 0.040   86(14.1)                 55(16.4)    0.81(0.56--1.15), 0.24
  New or worsening nephropathy                      28(4.5)            9(2.8)                   1.57(0.70--3.54), 0.27    36(5.9)                  25(7.5)     0.77(0.44--1.34), 0.35
  New or worsening retinopathy                      57(9.2)            21(6.6)                  1.65(0.97--2.82), 0.065   57(9.4)                  36(10.7)    0.924(0.60--1.43), 0.72
                                                                                                                                                               
  Secondary clinical outcomes                                                                                                                                  
  Coronary events                                   69(11.1)           22(6.9)                  1.80(1.09--2.98), 0.023   65(10.7)                 42(12.5)    0.90 (0.60--2.60), 0.61
  Heart disease                                     76(12.2)           29(9.1)                  1.42(0.91--2.21), 0.12    80(13.1)                 50(14.9)    0.91(0.64--1.29), 0.60
  Cerebrovascular events                            68(11.0)           31(9.7)                  1.19(0.77--1.85), 0.43    48(7.9)                  41(12.2)    0.61(0.40--0.93), 0.023
  All macrovascular events                          144(23.2)          63(19.7)                 1.26(0.93--1.71), 0.14    128(21.0)                85(25.4)    0.82(0.61--1.09), 0.16
  Visual deterioration                              127(20.5)          56(17.6)                 1.14(0.83--1.57), 0.42    87(14.3)                 46(13.7)    1.03(0.71--1.49), 0.88
  New or worsening microalbuminuria                 23(3.7)            17(5.3)                  0.60(0.32--1.15), 0.12    36(5.9)                  11(3.3)     2.23(1.08--4.60), 0.030
  All microvascular events                          211(34.0)          90(28.2)                 1.25(0.97--1.62), 0.079   188(30.9)                99(29.6)    1.06(0.82--1.36), 0.66
  Death from any cause                              45(7.2)            14(4.4)                  1.96(1.02--3.75), 0.044   34(5.6)                  22(6.6)     0.86(0.48--1.54), 0.62
  Neuropathy                                        29(4.7)            11(3.4)                  1.35(0.67--2.73), 0.41    24(3.9)                  11(3.3)     1.28(0.60--2.70), 0.53

HR = Hazard Ratio, the effects of treatment between *TRIB3* (c. 251, A \> G) AA and AG/GG genotypes (hazard ratios and p-values) were estimated from survival-cox regression models with backward LR adjustment for baseline available data.
